3月14日 - ** 制药商ANI Pharmaceuticals ANIP.O股价上涨2%至62.70美元
** 该公司称 (link)，美国食品和药物管理局已扩大批准Iluvien用于治疗影响眼球后段的慢性非感染性葡萄膜炎(NIU-PS)
** NIU-PS的特征是眼睛视网膜或视神经发炎。
** Iluvien已被FDA批准用于治疗另一种名为糖尿病黄斑水肿的眼病$(DME.AU)$
** 公司计划今年晚些时候在美国市场上以联合标签销售 Iluvien。
** 截至上次收盘，ANIP 在过去 12 个月中下跌了 7.2
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.